{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:42:20Z","timestamp":1783615340848,"version":"3.55.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.clinthera.2007.07.020","type":"journal-article","created":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T11:24:06Z","timestamp":1188991446000},"page":"1325-1337","source":"Crossref","is-referenced-by-count":48,"title":["Comparison of Botulinum Neurotoxin Preparations for the Treatment of Cervical Dystonia"],"prefix":"10.1016","volume":"29","author":[{"given":"Mary Ann","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich","family":"Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Tanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandler E.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. David","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.07.020_bib1","series-title":"Movement Disorders 2","first-page":"332","article-title":"Classification and investigation of dystonia","author":"Fahn","year":"1987"},{"key":"10.1016\/j.clinthera.2007.07.020_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0304-3959(96)03296-4","article-title":"Pain in spasmodic torticollis","volume":"69","author":"Kutvonen","year":"1997","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2007.07.020_bib3","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/1531-8257(199911)14:6<1043::AID-MDS1026>3.0.CO;2-3","article-title":"Painful cervical dystonia: Clinical features and response to treatment with botulinum toxin","volume":"14","author":"Tarsy","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.41.7.1088","article-title":"Cervical dystonia: Clinical findings and associated movement disorders","volume":"41","author":"Jankovic","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: Clinical characteristics","volume":"6","author":"Chan","year":"1991","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0303-8467(94)90072-8","article-title":"Idiopathic spasmodic torticollis: A survey of the clinical syndromes and patients' experiences","volume":"96","author":"van Herwaarden","year":"1994","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.clinthera.2007.07.020_bib7","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.10127","article-title":"Impact of cervical dystonia on quality of life","volume":"17","author":"Camfield","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib8","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib9","first-page":"155","article-title":"The origin, structure, and pharmacological activity of botulinum toxin","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharrnacol Rev"},{"key":"10.1016\/j.clinthera.2007.07.020_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis","volume":"2","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2007.07.020_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/PL00007848","article-title":"A ran- domized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulktoxin source for the treatment of cervical dystonia","volume":"249","author":"Naumann","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation ofcalcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2007.07.020_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.71.2.193","article-title":"Health related quality of life is improved by botulinum neurotoxin type A in long-term treated patients with focal dysronia","volume":"71","author":"Hilker","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2007.07.020_bib14","series-title":"Botulinurn Neurotoxin and Tetanus Toxin","first-page":"3","article-title":"Bacterial sources of closrridial neuroroxins","author":"Harheway","year":"1989"},{"key":"10.1016\/j.clinthera.2007.07.020_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0733-8635(03)00022-6","article-title":"Dysporr","volume":"22","author":"Markey","year":"2004","journal-title":"Derrnatol Clin"},{"key":"10.1016\/j.clinthera.2007.07.020_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0733-8635(03)00070-6","article-title":"Myobloc","volume":"22","author":"Flynn","year":"2004","journal-title":"Derrnatol Clin"},{"key":"10.1016\/j.clinthera.2007.07.020_bib17","series-title":"Dystonia: Etiology, Clinical Features, and Treatment","first-page":"93","article-title":"Pharmacology of botulinum toxin therapy","author":"Brin","year":"2004"},{"key":"10.1016\/j.clinthera.2007.07.020_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","article-title":"Comparison of two borulinum-toxin preparations in the treatment of essential blepharospasm","volume":"235","author":"Nussgens","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib19","first-page":"459","article-title":"Respective potencies of Borox and Dysporr: A double blind, randomised, crossover study in cervical dysronia","volume":"72","author":"Ranoux","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2007.07.020_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079905X36396","article-title":"Safety, effectiveness, and duration of effect of Borox after switching from Dysporr for blepharospasm, cervical dysronia, and hemifacial spasm dysronia, and hemifacial spasm","volume":"21","author":"Bihari","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2007.07.020_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000067023","article-title":"Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis","volume":"49","author":"Dressier","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","article-title":"A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia","volume":"64","author":"Odergren","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2007.07.020_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00002826-199106000-00011","article-title":"Electromyographic guidance of botulinum toxin treatment in cervical dysronia","volume":"14","author":"Dubinsky","year":"1991","journal-title":"Clin Neuropharrnacol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20468","article-title":"Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dysronia and blepharospasm: The REAL DOSE study","volume":"20","author":"Marchetti","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dysronia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib27","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dysronia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/014107689208500906","article-title":"Borulinum toxin treatment of spasmodic torticollis","volume":"85","author":"Anderson","year":"1992","journal-title":"J R Soc Med"},{"key":"10.1016\/j.clinthera.2007.07.020_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF02337443","article-title":"Borulinum A toxin injection in patients with blepharospasm, torti-collis and hemifacial spasm","volume":"11","author":"Berardelli","year":"1990","journal-title":"Ital J Neurol Sd"},{"key":"10.1016\/j.clinthera.2007.07.020_bib31","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hed.2880120504","article-title":"Botulinum A toxin for the treatment of spasmodic torticollis: Dysphagia and regional toxin spread","volume":"12","author":"Borodic","year":"1990","journal-title":"Head Neck"},{"key":"10.1016\/j.clinthera.2007.07.020_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00006534-199102000-00010","article-title":"Botulinum A toxin for the treatment of adult-onset spasmodic torticollis","volume":"87","author":"Borodic","year":"1991","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.clinthera.2007.07.020_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF02850184","article-title":"Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia","volume":"22","author":"Brashear","year":"2005","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2007.07.020_bib34","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/S0149-2918(00)83049-0","article-title":"Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: A retrospective chart review","volume":"22","author":"Brashear","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2007.07.020_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","article-title":"Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm","volume":"2","author":"Brin","year":"1987","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00002826-199404000-00008","article-title":"Determining a dose-effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia","volume":"17","author":"Buchman","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib37","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1212\/WNL.42.4.878","article-title":"Botulinum toxin injection for spasmodic torticollis: Increased magnitude of benefit with electromyographic assistance","volume":"42","author":"Cornelia","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib38","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1212\/WNL.42.7.1307","article-title":"Dysphagia after botulinum toxin injections for spasmodic torticollis: Clinical and radiologic findings","volume":"42","author":"Cornelia","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1212\/WNL.39.1.80","article-title":"Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis","volume":"39","author":"Gelb","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib40","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","article-title":"Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of-spasmodic torticollis","volume":"40","author":"Greene","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib41","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of-various movement disorders over a 10-year period","volume":"17","author":"Hsiung","year":"2002","journal-title":"MovDisord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/jnnp.53.8.633","article-title":"Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm","volume":"53","author":"Jankovic","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2007.07.020_bib43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","article-title":"Botulinum toxin injections for cervical dystonia","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib44","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archneur.1991.00530240057020","article-title":"Clinical correlates of response to botulinum toxin injections","volume":"48","author":"Jankovic","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib45","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib46","first-page":"355","article-title":"Failure of-fixed-dose, fixed muscle injection of botulinum toxin in torticollis","volume":"13","author":"Koller","year":"1990","journal-title":"Clin Neuro-pharmacol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib47","first-page":"279","article-title":"Treatment ofdystonia with botulinum A toxin: A retrospective study of 170 patients","volume":"4","author":"Kwan","year":"1998","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.clinthera.2007.07.020_bib48","first-page":"71","article-title":"The finding and evaluation of EMG-guided BOTOX injection in cervical dystonia","volume":"13","author":"Lee","year":"2004","journal-title":"Acl:a Neurol Taiwan"},{"key":"10.1016\/j.clinthera.2007.07.020_bib49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.5694\/j.1326-5377.1990.tb125354.x","article-title":"Treatment of idiopathic spasmodic torticollis with botulinum-A toxin: A pilot study of 19 patients","volume":"152","author":"Lorentz","year":"1990","journal-title":"MedJ Aust"},{"key":"10.1016\/j.clinthera.2007.07.020_bib50","first-page":"189","article-title":"Double-blind, placebo-controlled study of botulinum toxin injections in the treatment of cervical dystonia","volume":"94","author":"Lu","year":"1995","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.clinthera.2007.07.020_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0303-8467(90)90095-M","article-title":"Responsiveness of idiopathic spasmodic torticollis to botulinum A toxin injection. A critical evaluation of five cases","volume":"92","author":"Maurri","year":"1990","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.clinthera.2007.07.020_bib52","first-page":"337","article-title":"Efficacy and safety of a new bulk toxin ofbotulinum toxin in cervical dystonia: A blinded evaluation","volume":"22","author":"Racette","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib53","first-page":"403","article-title":"Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore","volume":"39","author":"Tan","year":"1998","journal-title":"Singapore Med J"},{"key":"10.1016\/j.clinthera.2007.07.020_bib54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/01.wnl.0000174433.76707.8c","article-title":"Autonomic function after botulinum toxin type A or B: A double-blind, randomized trial","volume":"65","author":"Tintner","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib55","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1017\/S031716710003540X","article-title":"A pilot study on the use of botulinum toxin in spasmodic torticollis","volume":"12","author":"Tsui","year":"1985","journal-title":"Can J Neurol Sci"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2007.07.020_bib56","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1017\/S0317167100038063","article-title":"Local treatment of spasmodic torticollis with botulinum toxin","volume":"14","author":"Tsui","year":"1987","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.clinthera.2007.07.020_bib57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000116936","article-title":"Effectiveness of botulinum toxin in the treatment of spasmodic torticollis","volume":"33","author":"Boghen","year":"1993","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.870060210","article-title":"Treatment of idiopathic spasmodic torticollis with botulinum toxin A: A double-blind study on twenty-three patients","volume":"6","author":"Lorentz","year":"1991","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000116805","article-title":"Botulinum toxin as a treatment for blepharospasm, spasmodic torticollis and hemifacial spasm","volume":"32","author":"Albanese","year":"1992","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib60","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jnnp.53.8.640","article-title":"Botulinum toxin treatment in spasmodic torticollis","volume":"53","author":"Blackie","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2007.07.020_bib61","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","article-title":"Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial","volume":"46","author":"Brans","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib62","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF00867425","article-title":"Botulinum toxin in cervical dystonia: Low dosage with electromyographic guidance","volume":"242","author":"Brans","year":"1995","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib63","first-page":"447","article-title":"Botulinum toxin in the treatment of Clinical Therapeutics dystonias-a hospital based study","volume":"51","author":"Gupta","year":"2003","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.clinthera.2007.07.020_bib64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","article-title":"Long-term follow-up of cervical dystonia patients treated with botulinum toxin A","volume":"19","author":"Haussermann","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib65","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1468-1331.1997.tb00382.x","article-title":"Long-term follow-up by video of cervical dystonia treated with botulinum toxin","volume":"4","author":"Jamieson","year":"1997","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib66","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/026921559400800414","article-title":"Botulinum therapy: Clinical and financial considerations","volume":"8","author":"Jordan","year":"1994","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.clinthera.2007.07.020_bib67","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency","volume":"246","author":"Kessler","year":"1999","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib68","first-page":"29","article-title":"Local treatment of spasmodic torticollis with botulinum toxin","volume":"39","author":"Kostic","year":"1990","journal-title":"Neurologija"},{"key":"10.1016\/j.clinthera.2007.07.020_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00839202","article-title":"Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin","volume":"239","author":"Lees","year":"1992","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib70","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/jnnp.54.9.813","article-title":"A double blind trial ofbotulinum toxin \u201cA\u201d in torticollis, with one year follow up","volume":"54","author":"Moore","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2007.07.020_bib71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport","volume":"64","author":"Poewe","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2007.07.020_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00839206","article-title":"Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients","volume":"239","author":"Poewe","year":"1992","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000008121","article-title":"Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study","volume":"43","author":"Rollnik","year":"2000","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib74","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib75","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.880180708","article-title":"Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin","volume":"18","author":"Van den Bergh","year":"1995","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2007.07.020_bib76","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/apmr.2001.21843","article-title":"Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: A comparative study between a home and a clinic treatment service","volume":"82","author":"Whitaker","year":"2001","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.clinthera.2007.07.020_bib77","first-page":"195","article-title":"The incidence and nature of dysphagia following botulinum toxin injections for torticollis: A prospective study of 123 patients","volume":"7","author":"Whurr","year":"1999","journal-title":"J Med Speech Language Pathol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib78","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s004150170028","article-title":"Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: Results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study","volume":"248","author":"Wissel","year":"2001","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib79","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/jnnp.51.7.920","article-title":"Botulinum toxin in spasmodic torticollis","volume":"51","author":"Stell","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2007.07.020_bib80","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mds.20290","article-title":"Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia","volume":"20","author":"Berman","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib81","first-page":"227","article-title":"Botulinum toxin type B: An open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients","volume":"78","author":"Cullis","year":"1998","journal-title":"Adv Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib82","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","article-title":"Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure","volume":"250","author":"Dressier","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib83","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/mds.20531","article-title":"Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia","volume":"20","author":"Factor","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib84","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.870120526","article-title":"BotB (botulinum toxin type B): Evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study)","volume":"12","author":"Truong","year":"1997","journal-title":"MovDisord"},{"key":"10.1016\/j.clinthera.2007.07.020_bib85","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1212\/WNL.45.11.2109","article-title":"Botulinum toxin type B in the treatment of cervical dystonia: A pilot study","volume":"45","author":"Tsui","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.07.020_bib86","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1468-1331.2005.01095.x","article-title":"The use ofbotulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A--initial experiences","volume":"12","author":"Barnes","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib87","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0041-0101(01)00101-5","article-title":"A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice","volume":"39","author":"Aoki","year":"2001","journal-title":"Toxicon"},{"key":"10.1016\/j.clinthera.2007.07.020_bib88","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0041-0101(02)00086-7","article-title":"Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety","volume":"40","author":"Aoki","year":"2002","journal-title":"Toxicon"},{"key":"10.1016\/j.clinthera.2007.07.020_bib89","unstructured":"Aoki KR, Sartorius A, Ardila C, et al. Pharmacology of Botox, Dysport, Myobloc and BTX-A in animal models of safety and efficacy. Presented at: 5th International Conference on Basic and Therapeutic Aspects of M.A. Chapman et al. Botulinum and Tetanus Toxins; June 23-25, 2005; Denver, Colo."},{"key":"10.1016\/j.clinthera.2007.07.020_bib90","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF03033931","article-title":"Botulinum neurotoxin\u2014from laboratory to bedside","volume":"9","author":"Foster","year":"2006","journal-title":"Neurotox Res"},{"key":"10.1016\/j.clinthera.2007.07.020_bib91","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2133.2003.05620.x","article-title":"A double-blind, randomized, comparative study of Dysport vs Botox in primary palmar hyperhidrosis","volume":"149","author":"Simonetta Moreau","year":"2003","journal-title":"BrJ Dermatol"},{"key":"10.1016\/j.clinthera.2007.07.020_bib92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000048297","article-title":"Effect of botulinum toxin A on facial wrinkle lines in Koreans","volume":"216","author":"Lew","year":"2002","journal-title":"Opkthalmologica"},{"key":"10.1016\/j.clinthera.2007.07.020_bib93","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0006-3495(00)76456-3","article-title":"Protein diffusion in living skeletal muscle fibers: Dependence on protein size, fiber type, and contraction","volume":"79","author":"Papadopoulos","year":"2000","journal-title":"Biophysj"},{"key":"10.1016\/j.clinthera.2007.07.020_bib94","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-1119(03)00792-3","article-title":"Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain","volume":"315","author":"Zhang","year":"2003","journal-title":"Gene"},{"key":"10.1016\/j.clinthera.2007.07.020_bib95","series-title":"Biomedical Aspects of Botulism","first-page":"247","article-title":"Production, purification and toxoiding of CIostridium botulinum type A toxin","author":"Hambleton","year":"1981"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2007.07.020_bib96","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/00002508-200211001-00002","article-title":"Therapeutic use of botulinum toxins: Background and history","volume":"18","author":"Setler","year":"2002","journal-title":"ClinJ Pain"},{"key":"10.1016\/j.clinthera.2007.07.020_bib97","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2014Dysport and Botox\u2014assuming a ratio of 4:1","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov Disord"},{"issue":"Suppl 8","key":"10.1016\/j.clinthera.2007.07.020_bib98","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1002\/mds.20066","article-title":"Clinical comparability of marketed formulations of botulinum toxin","volume":"19","author":"Sampaio","year":"2004","journal-title":"Mov Disord"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807002123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807002123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T01:23:48Z","timestamp":1684027428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807002123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0149291807002123"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.07.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}